SQUIRE, trial summary

A randomised clinical trial investigating the effect of versus in

NCT00981058    Lancet Oncol 2015;16:763-74  




Studied treatment
Control treatment



Patients
Group sizes -9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI0,22,01,0


Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, B├ílint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74     [PMID: 26045340]   link to pdf  



Registering number NCT00981058 (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: